People · Operator
Named in public records as an officer, director or promoter · active 2020–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Capstan Therapeutics, Inc. | — | Biotechnology | Series C | $227.0M | $881.9M | 2021 |
| Mediar Therapeutics, Inc. | — | Biotechnology | Series C | $127.9M | $194.6M | 2022 |
| TRex Holdings Inc. | — | Biotechnology | Series C | $42.3M | $329.3M | 2024 |
| Magnolia Neurosciences Corp | — | Biotechnology | Series B | $26.4M | $724.5M | 2020 |
Michael Baran at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Baran on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nandita Shangari | 2 | 4 |
| Asish Xavier | 1 | 18 |
| Michael Ross | 1 | 18 |
| Steve Gillis | 1 | 13 |
| Thong Le | 1 | 12 |
| Joel Marcus | 1 | 9 |
| Alexandra Cantley | 1 | 8 |
| Peter Hirth | 1 | 7 |
| Erez Chimovits | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Carol Gallagher | 1 | 6 |
| Laura Shawver | 1 | 6 |
| Meredith Fisher | 1 | 6 |
| David Schubert | 1 | 6 |
| Peter Parker | 1 | 6 |
| Ian Howes | 1 | 5 |
| M. Johnston Erwin | 1 | 5 |
| Joel Johnston Marcus | 1 | 5 |
| Kendall Mohler | 1 | 5 |
| Brian Hubbard | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.